A Programmed Cell Death Protein 1 Pathway-Derived Prognostic Transcriptomic Signature in Bladder Cancer: Development in TCGA-BLCA and Evaluation in Independent Cohorts
Authors:
- Hao-Han ChangHCHao-Han Chang
- Pai-Chi TengPTPai-Chi Teng
- Chia-Hsin LiuCLChia-Hsin Liu
- Yung-Lun LinYLYung-Lun Lin
- Shu-Chi WangSWShu-Chi Wang
- Bo-Ying BaoBBBo-Ying Bao
- Hsin-Chih YehHYHsin-Chih Yeh
- Chih-Pin ChuuCCChih-Pin Chuu
- Jiun-Hung GengJGJiun-Hung Geng
- Li-Hsin ChangLCLi-Hsin Chang
- Tsz-Yi TangTTTsz-Yi Tang
- Hsien-Che OuHOHsien-Che Ou
Open Access
- 13 October 2026
- journal article
- research article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (10) , 1056
Abstract
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) have changed the treatment of advanced bladder cancer, but only a minority of patients benefit. We asked whether expression of PD-1 pathway genes carries prognostic information in bladder cancer. Sixty-eight genes annotated to the PD-1 signaling, CD28 co-stimulation, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitory signaling pathways in Reactome were examined in The Cancer Genome Atlas bladder urothelial carcinoma cohort (TCGA-BLCA). Genes differentially expressed between tumor and normal tissue were entered into a least absolute shrinkage and selection operator (LASSO) Cox model, yielding a seven-gene risk score (FYN, GRAP2, TRIB3, MAP3K8, AKT3, CD274, and CD80). In TCGA-BLCA (n = 404), the risk score was associated with overall survival independently of age, sex, and stage (hazard ratio [HR] per standard deviation 1.24, 95% confidence interval [CI] 1.11–1.39) and modestly improved discrimination over clinical variables (concordance index [C-index] 0.630 to 0.664). With coefficients and standardization fixed in advance, the score was not associated with cancer-specific survival in GSE13507 (n = 165; HR per standard deviation 1.21, 95% CI 0.83–1.77) or with outcome in four further independent cohorts, including an atezolizumab-treated cohort; in a second, smaller ICI-treated cohort it was associated with shorter survival. Gene selection was unstable under bootstrap resampling, and the signature’s associations with transcriptome-inferred immune indices were limited. This PD-1 pathway-derived signature should therefore be regarded as exploratory; its prognostic value outside TCGA-BLCA is not supported by the available evidence.Keywords
Funding Information
- National Science and Technology Council, Taiwan (NSTC 113-2926-I-037-501-G)
- National Science and Technology Council, Taiwan (NSTC 114-2314-B-037-006)
- National Science and Technology Council, Taiwan (NSTC 114-2314-B-037-026)
- National Science and Technology Council, Taiwan (NSTC 113-2311-B-039-001-MY3)
- National Science and Technology Council, Taiwan (NSTC 115-2311-B-039-002-MY3)
- National Science and Technology Council, Taiwan (NSTC 115-2314-B-037-034-MY3)
- National Science and Technology Council, Taiwan (NSTC 115-2321-B-037-008)
- Kaohsiung Medical University (KMU-DK(B)-114004-1)
- Kaohsiung Medical University (KT114P007)
- Kaohsiung Medical University Chung-Ho Memorial Hospital (KMUH111-1M45)
- China Medical University (CMU111-IP-04)
- China Medical University (CMU112-MF-25)
- China Medical University (CMU113-MF-05)
- China Medical University (CMU114-MF-07)
- China Medical University Hospital (DMR-112-237)
This publication has 84 references indexed in Scilit:
- Outcomes Following Immune Checkpoint Inhibitor Treatment of Patients With Microsatellite Instability-High CancersJAMA Oncology, 2020
- A Consensus Molecular Classification of Muscle-invasive Bladder CancerEuropean Urology, 2020
- Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018European Urology, 2018
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsCell, 2018
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaJAMA Oncology, 2017
- miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8Biochemical and Biophysical Research Communications, 2016
- KLF5 promotes cell migration by up‐regulating FYN in bladder cancer cellsFEBS Letters, 2016
- Machine learning applications in cancer prognosis and predictionComputational and Structural Biotechnology Journal, 2014
- Overexpression of CK20, MAP3K8 and EIF5A correlates with poor prognosis in early-onset colorectal cancer patientsJournal of Cancer Research and Clinical Oncology, 2013
- Chemoprevention of bladder cancerWorld Journal of Urology, 2006